BIOVENTIX PLC

Director's Dealing • Oct 28, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Bioventix Plc - Director/PDMR Shareholding

PR Newswire

London, October 28

Bioventix plc

(“Bioventix” or the “Company”)

Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 25 October 2019 of the following transaction in its ordinary shares of 5 pence each (“Ordinary Shares”):

Director	Position	Ordinary Shares sold	Sale price per Ordinary Share	Ordinary Shares held subsequently	Percentage of issued share capital held subsequently
Ian Nicholson and Persons Closely Associated	Non-Executive Chairman	2,500	3,158.67p	15,500	0.3%

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.        Details of the person discharging managerial responsibilities / person closely associateda)NamesIan Nicholson (Non-Executive Chairman)2.        Reason for the Notificationa)Position/statusSee 1(a) aboveb)Initial notification/AmendmentInitial notification3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBioventix plcb)LEI213800225MHX7LZQY1084.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the Financial instrument, type of instrumentOrdinary shares of 5 pence (“Ordinary Shares”)Identification codeGB00B4QVDF07b)Nature of the transactionSale of Ordinary Sharesc)Price(s) and volume(s)

Price(s)	Volume(s)
3,158.67p	2,500

d)Aggregated information:

·      Aggregated volume

·      PriceSee 4(c)e)Date of the transaction25 October 2019f)Place of the transactionLondon Stock Exchange, AIM Market (XLON)

For further information please contact:

Bioventix plc Peter Harrison	Chief Executive Officer	Tel: 01252 728 001
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane	Corporate Finance ECM	Tel: 020 7220 0500

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.